<DOC>
	<DOC>NCT02844309</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed Waldenstr√∂m macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintenance therapy.</brief_summary>
	<brief_title>The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM</brief_title>
	<detailed_description>Enrolled patients will accept maximum 8 cycles of thalidomide plus cyclophosphamide and dexamethasone. if a partial remission response or better is achieved, thalidomide plus prednisone maintenance therapy will be given for no more than two years.</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1. Aged &gt;=18 years 2. diagnosed with WM 3. Untreated or mild treated without standard regimens,especially untreated with rituximab and/or bortezomib 4. symptom patients 5. with lifeexpectancy more than 3 months. 1. diagnosed with other malignancies outside BNHL within one year(including active centre neural system lymphoma) 2. Transformed lymphoma 3. liver or renal function lesion unrelated to lymphoma 4. serious complications such as uncontrolled diabetes,gastric ulcer or other serious angiocardiopathy determined by the physician 5. HIV positive or active HBV infection or other uncontrolled systematic infection 6. clinical central nervous dysfunction 7. serious surgery within 30 days 8. pregnancy or baby nursing period or uncontracepted childbearing period woman; 9. allergy to the trail drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>